Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 73963-72-1 | Product Number: C2587
Cilostazol
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 1G |
$105.00
|
1 | 1 | ≥80 |
|
| 5G |
$355.00
|
3 | 1 | ≥60 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | C2587 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__0H__2__7N__5O__2 = 369.47 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 73963-72-1 |
| Reaxys Registry Number | 3632107 |
| PubChem Substance ID | 160870980 |
| Merck Index (14) | 2277 |
| MDL Number | MFCD00866780 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Melting point | 158.0 to 162.0 °C |
Properties (reference)
| Melting Point | 160 °C |
| Maximum Absorption Wavelength | 257(MeOH) nm |
| Solubility in water | Insoluble |
| Solubility (slightly sol. in) | Methanol |
| Solubility (insoluble in) | Ether |
GHS
Related Laws:
| RTECS# | VC8277500 |
Transport Information:
| HS Number | 2933.99.7500 |
Application
Cilostazol: A Selective Inhibitor of Cyclic Nucleotide Phosphodiesterase 3 (PDE3)
Cilostazol is originally developed as a selective inhibitor of cyclic nucleotide phosphodiesterase 3 (PDE3). PDE3 inhibition in platelets and vascular smooth muscle cells is expected to provide an antiplatelet effect and vasodilatation, with therapeutic focus on cAMP. Recently, it has been reported that cilostazol is effective in vascular dementia associated with a cerebral ischemia. (The product is for research purpose only.)
References
- Effect of cilostazol on platelet aggregation and experimental thrombosis
- Y. Kimura, T. Tani, T. Kanbe, K. Watanabe, Arzneim.-Forsch. 1985, 35, 1144.
- Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture
- Cilostazol as a unique antithrombotic agent
- Phosphodiesterase III inhibition promotes differentiation and survival of oligodendrocyte progenitors and enhances regeneration of ischemic white matter lesions in the adult mammalian brain
- Cilostazol prevents amyloid β peptide25-35-induced memory impairment and oxidative stress in mice
Application
Dissolution Studies
Reference
- Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs
PubMed Literature
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.